Imunon, Inc.

Contributing Author

Recent Articles by Imunon, Inc.

May-15	IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 IMNN GlobeNewswire
May-12	IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update IMNN GlobeNewswire
May-08	IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer IMNN GlobeNewswire
May-06	IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology IMNN GlobeNewswire
May-05	IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 IMNN GlobeNewswire